Latent Tuberculosis in Pregnancy: A Systematic Review

Abstract

BackgroundIn countries with low tuberculosis (TB) incidence, immigrants from higher incidence countries represent the major pool of individuals with latent TB infection (LTBI). The antenatal period represents an opportunity for immigrant women to access the medical system, and hence for potential screening and treatment of LTBI. However, such screening and treatment during pregnancy remains controversial.ObjectivesIn order to further understand the prevalence, natural history, screening and management of LTBI in pregnancy, we conducted a systematic literature review addressing the screening and treatment of LTBI, in pregnant women without known HIV infection.MethodsA systematic review of 4 databases (Embase, Embase Classic, Medline, Cochrane Library) covering articles published from January 1st 1980 to April 30th 2014. Articles in English, French or Spanish with relevant information on prevalence, natural history, screening tools, screening strategies and treatment of LTBI during pregnancy were eligible for inclusion. Articles were excluded if (1) Full text was not available (2) they were case series or case studies (3) they focused exclusively on prevalence, diagnosis and treatment of active TB (4) the study population was exclusively HIV-infected.ResultsOf 4,193 titles initially identified, 208 abstracts were eligible for review. Of these, 30 articles qualified for full text review and 22 were retained: 3 cohort studies, 2 case-control studies, and 17 cross-sectional studies. In the USA, the estimated prevalence of LTBI ranged from 14 to 48% in women tested, and tuberculin skin test (TST) positivity was associated with ethnicity. One study suggested that incidence of active TB was significantly increased during the 180 days postpartum (Incidence rate ratio, 1.95 (95% CI 1.24–3.07). There was a high level of adherence with both skin testing (between 90–100%) and chest radiography (93–100%.). In three studies from low incidence settings, concordance between TST and an interferon-gamma release assay was 77, 88 and 91% with kappa values ranging from 0.26 to 0.45. In low incidence settings, an IGRA may be more specific and less sensitive than TST, and results do not appear to be altered by pregnancy. The proportion of women who attended follow-up visits after positive tuberculin tests varied from 14 to 69%, while 5 to 42% of those who attended follow-up visits completed a minimum of 6 months of isoniazid treatment. One study raised the possibility of an association of pregnancy/post-partum state with INH hepatitis (risk ratio 2,5, 95% CI 0.8–8.2) and fatal hepatotoxicity (rate ratio 4.0, 95% CI 0.2–258). One study deemed INH safe during breastfeeding based on peak concentrations in plasma and breast milk after INH administration.ConclusionPregnancy is an opportunity to screen for LTBI. Interferon-gamma release assays are likely comparable to tuberculin skin tests and may be used during pregnancy. Efforts should be made to improve adherence with follow-up and treatment post-partum. Further data are needed with respec...

Increased risk of active tuberculosis during pregnancy and postpartum: a register-based cohort study in Sweden

“…Maternal health controls represent an excellent opportunity to screen women belonging to risk groups for TB in order to initiate early diagnosis and treatment of active TB, or preventive therapy when indicated, as has been recommended in scientific publications 26,27…”

Effect of Pregnancy on Interferon Gamma Release Assay and Tuberculin Skin Test Detection of Latent TB Infection Among HIV-Infected Women in a High Burden Setting

“…[12–14] In settings with lower risk of TB transmission, a positive TST may reflect false positivity due to BCG vaccination rather than Mtb infection, leading to a higher proportion of TST+/IGRA−. [15] Additionally, most studies have been cross-sectional, and do not capture potential dynamic effects of peripartum stage on LTBI diagnostics.…”

A systematic review of adverse events of rifapentine and isoniazid compared to other treatments for latent tuberculosis infection

“…Both trials reported high rates of mortality and hospitalization in all arms 18,31. Reporting of drug safety in pregnancy was extremely limited for all regimens despite this issue being of considerable clinical interest both because patients may become pregnant while on therapy and because LTBI treatment may be warranted in select groups of pregnant patients at high risk of progression 89. A recent systematic review on LTBI treatment in pregnancy also found little data regarding adverse events 89.…”